The $900 Million Cost of a Shortage List Nobody's Steering

When a sterile-injectable plant floods, or a single manufacturer of a decades-old generic decides the margin isn't worth it, no one in Washington is required to notice fast, and no one is currently in charge of coordinating the response.▸ What happens instead is that a hospital pharmacy somewhere quietly substitutes, rations, or delays — and absorbs the cost of doing so. That absorption now has a price tag, and it is not small.

Every few years, Vizient — a group purchasing organization that runs a national survey of health-system pharmacy directors — asks hospitals to tally the hours their staff spend managing drug shortages: sourcing substitutes, reprogramming infusion pumps and electronic health records, fielding physician calls, documenting workarounds.▸ In 2019 the answer, extrapolated nationally, was just under $360 million a year. The most recent survey, released June 17, 2025 and covering calendar year 2023 across 132 responding hospitals, put the figure at nearly $900 million — more than double, built from an estimated 20 million staff hours. Pediatric hospitals fared worse than general ones, monitoring at least 25% more shortages on average, and 43% of respondents linked a shortage to an actual medication error, up from 38% in 2019.

None of that $900 million buys a single dose of medicine.▸ It is pure overhead — the cost of a supply chain that keeps breaking in the same predictable ways, paid for in pharmacist and nurse time instead of in prevention.

The shortage list itself is not shrinking on any stable trend — it is oscillating, and the most recent readings point up.▸ The University of Utah Drug Information Service, which maintains the shortage database on behalf of the American Society of Health-System Pharmacists (ASHP), counted an all-time high of 323 active shortages in the first quarter of 2024. That eased to 300 by the second quarter, and down to 270 by March 2025, then to 214 by the third quarter of 2025 — the lowest reading since early 2018, per Becker's Hospital Review. Since then it has turned back up: 216 in the fourth quarter of 2025, then 223 in the first quarter of 2026 — a second consecutive quarterly increase, according to an April 2026 ASHP report. Three-quarters of today's active shortages began in 2022 or later — this is not mostly legacy backlog, it is a live, recurring failure mode.

The federal government's own list runs far shorter than ASHP's — and that gap is itself a symptom.▸ The Government Accountability Office found the FDA was tracking just 102 drug shortages as of July 31, 2024, against ASHP's count of roughly three times that in the same window, because FDA's list only includes shortages manufacturers have formally reported under federal notification law — a narrower bar than ASHP's active-monitoring approach. GAO's real finding was structural: HHS had no formal mechanism to coordinate its own shortage-related work across agencies, and recommended one. HHS's response was to tell GAO that the department's Supply Chain Resilience Coordinator position — its only dedicated coordination role — was ending in May 2025, with nothing announced to replace it. Sterile injectable drugs, the GAO report notes, remain the category hit hardest — the same drugs that keep chemotherapy infusions and ICU crash carts running.

Shortage counts come from two different measurement methods — FDA's statutory shortage list and ASHP/University of Utah's broader monitoring database — and are not directly interchangeable; both are cited here for what each measures.